Prot# 6002-US-201: A Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) in Subjects with Restless Legs Syndrome

Project: Research project

Project Details

StatusFinished
Effective start/end date8/23/059/20/06

Funding

  • Ingenix Pharmaceutical Services, Inc. (6002-US-201)
  • Kyowa Hakko Kirin Pharma, Inc. (6002-US-201)